Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

This healthcare products distributor's business model can withstand a recession.

Buy This Warren Buffett-Owned Stock for 2023 and Beyond

The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.

McKesson (MCK) Announces Availability of FDA-Accepted Drug

Markel

Occidental Petroleum

All three of these Buffett stocks have trounced the market this year.

Warren Buffett Bought 19 Stocks in 2022; These 3 Are the Best Bets for 2023

Ally Financial

Citigroup

Jefferies Financial Group Inc

Taiwan Semiconductor Manufacturing

Buffett's company Berkshire Hathaway didn't sit around this year.

7 New Stocks Warren Buffett Bought in 2022

Amazon

Teladoc

Tesla

Before making a move, take a long-term view.

2023 Is Almost Here. Should You Keep Investing Right Now?

McKesson reported solid second quarter results. Not only is the business recession-resilient, it also settled the opioid litigations in 2022.

McKesson Corporation: Still Trading Below Intrinsic Value

Merck

Vertex Pharmaceuticals

Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.

3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns

Costco

FedEx

Are these the top defense stocks to invest in right now?

3 Defense Stocks To Watch In The Stock Market Now

Cardinal Health

Super Micro Computer

Outperforming the Zacks Oils and Energy sector in 2022 is no easy task. However, bulls have silently roamed in all three of these stocks, breaking the overall bearish trend we've become accustomed to.

3 Stocks Silently Outperforming Energy in 2022

AmerisourceBergen

Economic uncertainty hasn't been kind to Wall Street, but drug distributors — led by McKesson stock — have managed to weather the worst of the storm. The post McKesson Stock And Its Peers Carve Fat Gains From A Fearful Market appeared first on Investor's Business Daily.

McKesson Stock And Its Peers Carve Fat Gains From A Fearful Market

Becton, Dickinson and Co.

Dollar General

Kroger

Philip Morris

Raytheon Technologies

UnitedHealth Group

Although the market has rallied since the start of November, on rising hopes of a pivot on interest rates by the Federal Reserve (aka a “Fed pivot”), that doesn't necessarily mean it's time to abandon the best bear market stocks and dive back into “risk-on” types of plays. Even as the Fed, in light of data indicating that inflation may be cooling, could soon slow down the pace of subsequent rate hikes, according to one Fed official, it may not be until 2024 that the central bank starts to cut interest rates again.

The 7 Best Bear Market Stocks to Buy Now

Johnson & Johnson

Procter & Gamble

These stocks could grow Buffett's wealth -- and yours.

3 Warren Buffett Stocks to Buy Hand Over Fist Before 2023

McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.

McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why

Berkshire Hathaway has a 2.3% stake in this healthcare stock.

Is This Healthcare Giant a Buy for Dividend Growth Investors?

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Here's Why You Should Add McKesson (MCK) Stock Right Now

Archer-Daniels-Midland Company

Booz Allen Hamilton Hld

Darden Restaurants

Parker-Hannifin

Archer-Daniels-Midland (ADM), McKesson (MCK), ParkerHannifin (PH), Booz Allen Hamilton (BAH) and Darden Restaurants (DRI) could be compelling picks for your portfolio this Thanksgiving.

5 Solid Dividend Growth Stocks for Thanksgiving

Marathon Petroleum

Exxon Mobil

We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.

Buy These 5 Corporate Giants Flying High in Disappointing 2022

McKesson has many of the hallmarks of the type of stable company Berkshire Hathaway likes to own.

Warren Buffett Likes This Passive Income Stock

Activision Blizzard

Chevron

Globe Life Inc

Kraft Heinz

Coca-Cola

T-Mobile US

Warren Buffett is having a much better year than most S&P 500 investors. And he can thank a handful of stocks for that.

Warren Buffett Makes All His Money From Just 11 Stocks

Caterpillar

Humana

O'Reilly Automotive

We have narrowed our search to five U.S. corporate behemoths with solid growth potential. These are: HUM, MPC, CAT, MCK and ORLY.

October CPI Data Raises Hope for a Soft Landing: 5 Top Picks

Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, MCK and ABC.

3 Dental Supplies Stocks to Watch Amid Industry Headwinds

3 Reasons Growth Investors Will Love McKesson (MCK)

H&R Block

Insperity

We have selected five dividend growth stocks ??? H&R Block (HRB), ParkerHannifin (PH), Archer-Daniels-Midland (ADM), Insperity (NSP) and McKesson (MCK)?

Top 5 Dividend Stocks to Cheer You Up This Holiday Season

Campbell Soup

Bear Market Investing: Should You Buy Today's Top Performers?

McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.

News for McKesson Stock (MCK)